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IMPORTANCE Deviation from normal adolescent brain development precedes manifestations
of manymajor psychiatric symptoms. Such altered developmental trajectories in adolescents
may be linked to genetic risk for psychopathology.
OBJECTIVE To identify genetic variants associated with adolescent brain structure
and explore psychopathologic relevance of such associations.
DESIGN, SETTING, AND PARTICIPANTS Voxelwise genome-wide association study in a cohort of
healthy adolescents aged 14 years and validation of the findings using 4 independent samples
across the life span with allele-specific expression analysis of top hits. Group comparison of
the identified gene-brain association among patients with schizophrenia, unaffected siblings,
and healthy control individuals. This was a population-based, multicenter study combined
with a clinical sample that included participants from the IMAGEN cohort, Saguenay Youth
Study, Three-City Study, and Lieber Institute for Brain Development sample cohorts and UK
biobank whowere assessed for both brain imaging and genetic sequencing. Clinical samples
included patients with schizophrenia and unaffected siblings of patients from the Lieber
Institute for Brain Development study. Data were analyzed between October 2015 and April
2018.
MAIN OUTCOMES ANDMEASURES Graymatter volumewas assessed by neuroimaging
and genetic variants were genotyped by Illumina BeadChip.
RESULTS The discovery sample included 1721 adolescents (873 girls [50.7%]), with a mean
(SD) age of 14.44 (0.41) years. The replication samples consisted of 8690 healthy adults
(4497 women [51.8%]) from 4 independent studies across the life span. A nonsynonymous
genetic variant (minor T allele of rs13107325 in SLC39A8, a gene implicated in schizophrenia)
was associated with greater gray matter volume of the putamen (variance explained of 4.21%
in the left hemisphere; 8.66; 95% CI, 6.59-10.81; P = 5.35 × 10−18; and 4.44% in the right
hemisphere; t = 8.90; 95% CI, 6.75-11.19; P = 6.80 × 10−19) and also with a lower gene
expression of SLC39A8 specifically in the putamen (t127 = −3.87; P = 1.70 × 10
−4).
The identified association was validated in samples across the life span but was significantly
weakened in both patients with schizophrenia (z = −3.05; P = .002; n = 157) and unaffected
siblings (z = −2.08; P = .04; n = 149).
CONCLUSIONS AND RELEVANCE Our results show that amissensemutation in gene SLC39A8
is associated with larger gray matter volume in the putamen and that this association is
significantly weakened in schizophrenia. These results may suggest a role for aberrant ion
transport in the etiology of psychosis and provide a target for preemptive developmental
interventions aimed at restoring the functional effect of this mutation.
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T he adolescent brain undergoes substantial structuralchange, and deviations from the normal trajectory ofbrain development are thought to underlie many psy-
chiatric symptoms.1 Growth patterns of adolescent brain
development have been identified using longitudinal neuro-
imaging studies: decrease (eg, cortical regions, caudate,
and putamen), increase (eg, hippocampus), and inverted
U-shaped (eg, amygdala and thalamus).2-5 Twin studies have
demonstrated regionally specific changes in heritability dur-
ingdifferentphasesofbraindevelopment,6andsignificantage-
by-heritability interactions have been reported for gray mat-
ter volumes (GMV) in cortical and subcortical structures.7
Commongeneticassociationswithbothadolescentbrainstruc-
tures and risks for psychiatric disorders remain to be uncov-
ered.
Large-scale meta-analysis of genome-wide association
study (GWAS) is the state-of-the-art approach to detect novel
geneticvariantsassociatedwithbrainstructure.However,often
these studies are carried out in samples from heterogeneous
age groups to maximize the overall sample size,8 and large-
scaleGWASonadolescentbrain isnotavailableyet.Thus,much
less is known about genetic factors to provide us with infor-
mation about normal trajectories of brain development, and
deviations from normal trajectories have been implicated in
the pathophysiology of mental disorders.9-11 To increase the
statistical power to detect genetic associations in the devel-
oping adolescent brain, it is important to investigate a sample
with a narrow age range.10 This has already been demon-
strated in a 2014 twin study,12 in which the heritability esti-
mated from 89 twin pairs at the same age resembled esti-
mates givenby largemeta-analysis,withmore than 1250 twin
pairs fromdifferent age groups.13 Additional limitations inde-
tecting genetic associationsmight have been caused by using
atlas-basedbrain segmentationbecausebrain regions suchde-
fined can be genetically heterogeneous,14 thus potentially re-
sulting in false-negative observations. To address these limi-
tations, we investigated a cohort of more than 2000 healthy
adolescents aged 14 years (IMAGEN15) and combined voxel-
wise brain imaging with genome-wide association study
(vGWAS16).
Genetic associations on brain structures can emerge in a
particular developmental period or can present across the
life span.6,7 Thus, genetic factors might cause pervasive neu-
roanatomical aberrations that are linked to psychopathology
during a defined developmental period or across the life
span.9-11 To validate our findings and extend them to a wider
age range, we used 4 additional cohorts of healthy partici-
pants to characterize patterns of the identified associations
across the life span including the Saguenay Youth Study
(SYS17), Lieber Institute for Brain Development sample
(LIBD18), UK Biobank (UKB19), and Three-City Study (3C20).
For the identified genetic variants, we tested their cisregula-
tions on the expressions of nearby genes in brain tissues. To
test whether genetic associations of adolescent brain are dis-
rupted by psychopathology, we compared the identified
associations among patients with psychiatric disorder, unaf-
fected siblings, and healthy control individuals in clinical
sample.
Method
Participants
Discovery Sample and Samples Across the Life Span
The IMAGENstudy,15 apopulation-based longitudinal imaging
genetics cohort, recruited 2087 healthy adolescents aged 14
years, of which 1721 entered the vGWAS (eMethods 1 and 2 in
the Supplement). We also investigated 971 healthy partici-
pants from the adolescent SYS sample,17 272 healthy partici-
pants from the clinical LIBD sample,18 6932participants from
thepopulation-basedUKBcohort,19and515healthyelderlypar-
ticipants fromthe3Csample,21apopulation-basedcohortstudy
(eMethods 3-6 in the Supplement).
Clinical Sample
In the LIBD study of schizophrenia,18 we investigated 157
treated patients with chronic schizophrenia and 149 unaf-
fectedsiblingsofpatients (eMethods4 in theSupplement).The
IMAGENprojecthadobtainedethical approvalby the local eth-
ics committees, including King’s College London, University
of Nottingham, Trinity College Dublin, University of Heidel-
berg,TechnischeUniversitätDresden,Commissariatà l'Energie
Atomique et aux Energies Alternatives, and University Medi-
calCenter,UniversityofHamburg,Hamburg,Germany.ForSYS,
the institutional review boards of all participating institu-
tions approvedall studies reportedherein. Theparticipants of
the LIBD study were recruited as part the Clinical Brain Dis-
orders Branch Sibling Study of schizophrenia at the National
Institute ofMentalHealth (Daniel R.Weinberger, principal in-
vestigator). The study was approved by the institutional re-
view board of the Intramural Program of the National Insti-
tuteofMentalHealth.The3Cstudywasapprovedby theEthics
Committeeof theHôpital deBicêtre.All adultparticipantspro-
vided written informed consent after information on the re-
search procedures by each cohort study. For adolescent par-
ticipants in IMAGENandSYS,allparticipants’parentsprovided
written informedconsentafter informationontheresearchpro-
cedures andadolescentsprovided their assent afterwritten in-
formation.
Key Points
Question Is there any genetic variant associated with adolescent
brain development that can inform psychopathology of
schizophrenia?
Findings In this imaging genetics study of brain structure, a
significant association between amissensemutation in SLC39A8
(a gene previously associated with schizophrenia) and gray matter
volume in putamenwas discovered and replicated using 10 411
healthy participants from 5 independent studies. Compared with
healthy control individuals, such association was significantly
weakened in both patients with schizophrenia and unaffected
siblings.
Meaning Common genetic variant indicates an involvement of
neuronal ion transport in both pathophysiology of schizophrenia
and structural development of putamen.
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Measures
Genome-Wide Genotype Data
The IMAGEN blood samples were genotyped using either
Illumina Human610-Quad Beadchip or Illumina Human660-
QuadBeadchip.Afterqualitycontrol,466 114single-nucleotide
polymorphisms(SNPs)enteredthefollowinganalysis.Detailsof
thegenotypingandqualitycontrolareavailableinapublication22
and in eMethods 1 in the Supplement.
Structural Image Data
Structuralmagnetic resonance imaging (MRI)was performed
on3-Tscanners from3manufacturers (Siemens:5sites;Philips:
2 sites; and General Electric: 2 sites) following the Alzhei-
mer’s Disease Neuroimaging Initiative protocol modified for
the IMAGEN study. All data were preprocessed in Statistical
Parametric Mapping, version 8 using the Voxel-Based Mor-
phometry, version 8 toolbox, including segmentation, nor-
malization, modulation, and smoothing (eMethods 2 in the
Supplement).
Brain Expression Quantitative Trait Loci Database
In the UK Brain Expression Consortium (UKBEC23) database,
gene expression data are available for 10 brain regions from
134 neuropathologically free participants. For any vGWAS-
identifiedmutationonagene,we first testedwhether this SNP
was associatedwith expressionof this gene. Second,wewent
on to testwhether such an associationwas tissue specific and
whether this SNP also had cisregulations on expressions of
nearby (±1 Mb) genes. For this extended exploration, we cor-
rected formultiplecomparisonsbetweenthenumberofnearby
genesandthenumberofbrainareas (eMethods7 in theSupple-
ment).
Statistical Analysis
Voxelwise and Genome-Wide Association Study
On the discovery sample, we performed a GWAS on GMV of
each voxel in the brain (ie, 438 145 voxels labeled as per the
Automatically Anatomical Labeling template24). A signifi-
cant association was identified if a cluster hadmore than 217
(approximately 4/3 × π × [3.3970 × 1.645]3/1.53 voxels falling
into the 90% confidence interval of the smoothing kernel)
voxels with 2-sided P values surviving a Bonferroni correc-
tion (P < 2.4483 × 10−13, calculated by 0.05/438 145/466 114;
eMethods8 in the Supplement). Regions of interestwere then
established from the identified clusters, and GMV of each re-
gion of interest was calculated by adding the volumes of all
voxels within this region. Replications were mainly con-
ductedfor thesignificantclustersusingeachreplicationsample
(eMethods 9 in the Supplement formeta-analysis).We estab-
lished the 95% confidence interval of the statistics by 3000
bootstraps.
Summary-DatabasedMendelian Randomization
For the identified brain structure, we conducted summary-
databased Mendelian randomization (SMR) analysis by
a web-based application (MR-Base25; eMethods 10 in the
Supplement). Using Psychiatric Genomics Consortium 2014
GWAS results for schizophrenia26 as the outcome, we tested
whether the association between the identified brain struc-
ture and schizophrenia was significant and free of nonge-
netic confounders.27 A significant SMR resultmay suggest an
association between the exposure (brain volume) and the
outcome(schizophrenia)usingtheexposure-associatedgenetic
variant as an instrument because the random nature of ge-
netic variation mimics the design of randomized clinical
trials.25 Although significant SMR results require further bio-
logical validation,nonsignificant results at least indicate a lack
of association.28
Comparison Among Patients, Unaffected Siblings,
and Healthy Control Individuals
We first conducted power analysis to test whether we had
enough sample size to detect the previously identified ge-
netic associations in our clinical sample (eMethods 11 in the
Supplement). To compare the identified association in pa-
tients with schizophrenia or unaffected siblings with that in
healthy control individuals, we estimated its effect size using
correlationcoefficient.Partial correlationsbetweenGMVof the
regionsof interest andSNPswereestimatedcontrolling forage,
age × age, sex, IQ, total intracranial volume, and ratio of gray
and white matter volume over total intracranial volume. Be-
tween independentsamples,wecomparedeffectssizes (ie,par-
tial correlation coefficient) after transforming them into z sta-
tistics. The95%1-sidedupper boundwas establishedby3000
bootstraps for the difference between2partial correlations in
patients and their paired unaffected siblings, respectively.
Results
Demographics
In thediscovery sample of 1721 healthy adolescents (ofwhom
873were girls [50.7%]), the participantswere amean (SD) age
of 14.44 (0.41) years, while the replication samples of 8690
healthy participants (of whom 4497 were girls [51.8%]) had a
larger age range between 12 and 92 years. The clinical sample
used in this study had 157 patients with schizophrenia (of
whom 35were female [22.2%], with amean [SD] age of 34.82
[9.91] years) and 149 unaffected siblings of patients (ofwhom
85 were female [57.1%], with a mean [SD] age of 36.60 [9.44]
years). Further demographics and clinical features are listed
in eTable 1 in the Supplement.
Association of Schizophrenia Risk SNP rs13107325
With Putamen Volume
Applying voxelwise and GWAS (vGWAS) to the discovery
sample, we found that the minor T allele (a missense muta-
tion in gene SLC39A8) of SNP rs13107325 was associated
with larger volumes in bilateral putamen (left hemisphere:
t1705 = 8.66;P = 5.35 × 10−18; varianceexplained [VE] = 4.21%;
right hemisphere: t1705 = 8.90; P = 6.80 × 10−19; VE = 4.44%
right hemisphere), and these clusters were asymmetric be-
tween left and right hemispheres (Figure 1A-C). In addition,
we foundanassociationof theminorGallele of SNP rs7182018
(an intronvariant on lncRNARP11-624L4.1)with greaterGMV
of 2 clusters in bilateral central sulcus (left hemisphere:
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t1705 = 9.86; P = 1.25 × 10−22; VE = 5.39%; right hemisphere:
t1705 = 9.96; P = 4.54 × 10−23; VE = 5.50%; Figure 1D and E;
Table; eTables 2-4 in the Supplement; eFigure 1 for Manhat-
tan plots and QQ plots in the Supplement; eFigure 2 for dis-
tributions and bootstraps in the Supplement).
rs13107325 has been associated with schizophrenia in a
2014PsychiatricGenomicsConsortium(phase2)GWAS.26The
SMR using Psychiatric Genomics Consortium (phase 2) re-
sults as outcome identified the associations betweenGMVsof
the putamen clusters and schizophrenia (left putamen clus-
ter: b = 0.9388; SE = 0.1329; P = 1.61 × 10−12; right putamen
cluster: b = 3.444; SE = 0.4875;P = 1.607 × 10−12; eFigure 3 in
the Supplement). Considering that the SMR analysis identi-
fiednoassociationbetween thecentral sulcusandschizophre-
nia using any SNP within the neighboring region (±1 Mb) of
rs7182018asan instrumental variable (eFigure4 in theSupple-
ment), we concluded that rs7182018 is not associated with
schizophrenia.Analysesonrs7182018are found ineTables2-12
and eFigures 5-13 in the Supplement.
Independent Replications Across the Life Span
In the SYS sample of 971 healthy adolescents with a mean
(SD) age of 15.03 (1.84) years, we replicated the positive
associationof SNP rs13107325 in the left putamen (t964 = 3.70;
P = 1.16 × 10−4) but found no such association in the right pu-
tamen (t964 = −1.73; P = .08). The right putamen cluster was
affected by a greater variation of the insula in the SYS sample
because a part of the insula was mapped into this cluster
(eFigure 14 in the Supplement).
Using the UKB sample (mean [SD] age, 62.64 [7.41]
years; n = 6932), we replicated the positive associations
of rs13107325 with GMV of the putamen clusters (left hemi-
sphere: t6885 = 4.80; P = 8.16 × 10-7; VE = 0.33%; right hemi-
sphere: t6885 = 4.80; P = 8.16 × 10-7; VE = 0.60%). Given the
large sample size of this cohort, we further confirmed the sig-
nificance of the identified clusters using a SNP to whole-
brain approach with 10000 permutations at a cluster level
(eTable 11 in the Supplement). In another 2 independent
sampleswithmean(SD)agesof31.92 (9.50)years (LIBDsample,
Figure 1. Significant Associations Identified by Voxelwise and Genome-Wide Association Study
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n = 272) and 77.48 (5.12) years (3C sample, n = 515), we again
confirmed the identified positive associations (LIBD sample,
leftputamen: t264 = 4.93;P = 7.22 × 10−7;VE = 8.38%; rightpu-
tamen: t264 = 5.33;P = 1.05 × 10−7;VE = 9.65%;3Csample, left
putamen: t507 = 2.34; P = .01; VE = 1.07%; right putamen:
t507 = 2.28;P = .01; VE = 1.02%;Table; eTables 9 and 10 in the
Supplement; and eFigures 7-12 and 15-17 in the Supplement).
Association of rs13107325With Lower Expression Level
of SLC39A8 in Putamen
Usingtheexpressionquantitativetrait loci (eQTL)databasefrom
theUKBEC(n = 134,with112CCgenotypes,22CTgenotypes,and
0TTattheSNPrs13107325),wefoundthat thecarriersof therisk
allele(T)atrs13107325showedlowerexpressionofSLC39A8 (t127
= −3.87; 95% CI, −6.51 to −1.73; P = .0002) in the putamen
(Figure2AandB).Furthermore,wefoundthatdespitebrainwide
expressionofSLC39A8 (Figure2C),thiseQTLassociationwasspe-
cific for the putamen and was not detected in any of the other
brain regions (P < .0008, Bonferroni correction for 10 types of
braintissuesand6neighboringgenes) (Figure2D). Inadditionto
gene SLC39A8 (eTables 13 and 14 in the Supplement), we also
foundassociationsof rs13107325with lowergeneexpressionsof
NF-κB1 in thehippocampus(t120 = −3.62;95%CI,−6.31 to−1.28;
P = .0004),MANBA inthefrontalcortex(t125 =−3.73;95%CI,−5.93
to −1.84;P = .0003), andhigher expressionofCENPE in the oc-
cipital cortex (t127 = 3.69; 95%CI 1.72 to 6.10;P = .0003).
Gene-Brain AssociationWeakened by Genetic Risk
for Schizophrenia
Despite inconsistent structural neuroimaging results of the
putamen in schizophrenia (no difference,29,30 reduction,31 or
enlargement32-36ofstructurehavebeenreported), thisstructure
has longbeenassociatedwithbothelevateddopaminesynthe-
sis capacity37,38 and frontostriatal dysconnectivity39 in schizo-
phreniaand iskey to theeffectsof antipsychotic treatment40-43
by various methodologic approaches.38,39,44,45 To reduce the
confounding effects, we used unaffected siblings (carrying a
highergeneticriskforschizophrenia46butfreeoftheclinicalphe-
notypeand treatment effects18) of patientswith schizophrenia
to furthervalidate the involvementof the rs13107325-putamen
association in schizophrenia. We hypothesized that the
rs13107325-putamenassociationwassignificantlyweakened in
both patients and unaffected siblings compared with healthy
control individuals.Givena largeeffect size (r = 0.3117;n = 272)
in the healthy control individuals, power analysis (eMethods
11 in the Supplement) estimated a sample size of 102 for 95%
powerassuminga5%significance levelanda1-sidedtest.There-
fore, we had enough patients (n = 157) and unaffected siblings
(n = 149) in the LIBD study to detect such an association. We
foundthatthers13107325-putamenassociationintherighthemi-
spherebecameinsignificant inbothpatientsandunaffectedsib-
lings (Table).Thisdisruptingeffectmightbespecificbecausethe
rs7182018-CENassociation remainedsignificant inall 3 groups
(eTable5 intheSupplement).Comparedwithhealthycontrol in-
dividuals, patients had a significantly weakened rs13107325-
putamenassociation (z = −3.05;P = .002).Next,weconfirmed
thatsuchassociationwasweaker intheunaffectedsiblingscom-
paredwith thehealthy control individuals (z = −2.08;P = .04).
Inpatient-siblingpairs (n = 49),we found that theSNP-volume
associationwasweakerinpatientscomparedwithunaffectedsib-
lings (rpatient-rsibling = −0.25;95%upper1-sidedbound;−0.0143;
P = .04).
Table. Associations of a Schizophrenia-Risk SNP rs13107325
With the GrayMatter Volumes of 2 Putamen Clusters inMultiple Cohortsa
Sample and Cluster Volume, mean (SD), mL t (95% CI) P Value Variance Explained, %
IMAGENb
Left PUT 1.93 (0.35) 8.66 (6.59 to 10.81) 5.35 × 10−18 4.21
Right PUT 0.75 (0.09) 8.90 (6.75 to 11.19) 6.80 × 10−19 4.44
SYSc
Left PUT 1.60 (0.22) 3.70 (1.85 to 5.60) 1.16 × 10−4 1.40
Right PUT 0.81 (0.11) −1.73 (−3.54 to −0.04) .08d 0.31
LIBD HCe
Left PUT 1.59 (0.22) 4.93 (2.86 to 7.11) 7.22 × 10−7 8.38
Right PUT 0.65 (0.06) 5.33 (3.29 to 7.48) 1.05 × 10−7 9.65
UKBf
Left PUT 1.37 (0.28) 4.80 (2.97 to 6.72) 8.16 × 10−7 0.33
Right PUT 0.53 (0.09) 6.46 (4.48 to 8.41) 5.44 × 10−11 0.60
3Cg
Left PUT 1.11 (0.14) 2.34 (0.62 to 4.45) .01 1.07
Right PUT 0.48 (0.06) 2.28 (0.45 to 4.31) .01 1.02
LIBD SZh
Left PUT 1.57 (0.28) 2.01 (0.60 to 3.55) .02 2.00
Right PUT 0.65 (0.09) 0.17 (−1.46 to 1.78) .43 0.02
LIBD SBi
Left PUT 1.53 (0.21) 2.27 (0.23 to 4.09) .01 3.47
Right PUT 0.63 (0.06) 1.30 (−0.93 to 3.11) .10 1.16
Abbreviations: 3C, Three-City Study;
HC, healthy control individuals;
LIBD; Lieber Institute for Brain
Development; PUT, putamen;
SYS, Saguenay Youth Study;
SZ, patients with schizophrenia;
SB, unaffected siblings of patients;
SNP, single-nucleotide
polymorphism; UKB, UK biobank.
a Validations of positive associations
in different age groups. P values
were given by 1-tailed test .
The associations were estimated for
the volumes of the significant
clusters identified by our voxelwise
genome-wide association study.
The volume of a cluster was
calculated by adding up the volume
of each voxel within that cluster.
b n = 1721; Mean age, 14 years.
c n = 971; Mean age, 15 years.
d Two-tailed P value test because the
association went to an opposite
direction compared with the
hypothesis.
e n = 272; Mean age, 32 years.
f n = 6932; Mean age, 62 years.
g n = 515; Mean age, 77 years.
h n = 157; Mean age, 35 years.
i n = 149; Mean age, 37 years.
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Discussion
In this vGWAS, we discovered an rs13107325-putamen asso-
ciation in adolescent brains and confirmed this association
across the life span. Mendelian randomization analysis dem-
onstrated a significant association between putamen volume
and schizophrenia free of nongenetic confounders. Unaf-
fected siblings of patients showed a significant weakening of
the rs13107325-putamenassociation thatmaybeowing to the
genetic risk for schizophrenia. Together, these findings pro-
vide a new and testable hypothesis of an interaction between
thepathologyof schizophrenia and themechanismdetermin-
ing the putamen volume.
Single-nucleotidepolymorphismrs13107325 (located inan
exon of SLC39A8, chromosome 4) encodes a solute carrier
transporter ZIP8 expressed in the plasmamembrane andmi-
tochondria. SLC39A8 has been associated with schizophre-
nia by both large-scale GWAS47,48 and genetic genome-wide
DNA methylation analysis (brain tissues collected from 24
Figure 2. Gene Expression of SLC39A8 at Putamen and GrayMatter Volume at Putamen Shared CommonGenetic Controls
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probes used by Affymetrix were organized according to locations of their
starting base at chromosome 4). B, Comparison between gene expression
levels of SLC39A8 at putamenwith different genotypes at SNP rs13107325.
C, Comparison on gene expression levels (mean value and 95% confidence
interval) of SLC39A8 across 10 brain regions, including inferior olivary nucleus
(MEDU; subdissected from themedulla), putamen (PUTM; at the level of the
anterior commissure), substantia nigra (SNIG), cerebellar cortex (CRBL),
thalamus (THAL; at the level of the lateral geniculate nucleus), temporal cortex
(TCTX), intralobular white matter (WHMT), occipital cortex (OCTX), frontal
cortex (FCTX), and hippocampus (HIPP). D, Association patterns between SNP
rs13107325 and gene expressions in 10 brain regions. Genes with significant
associations (P < .0008, calculated by 0.05/10/6 by Bonferroni correction)
were labeled with gene names. bp Indicates base pairs.
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patients alongwith24healthy control individuals49). Thepos-
sible involvement of this gene in the psychopathology of
schizophrenia has been discussed since 201248 and has been
shown to involve immunologic processes, glutamatergic neu-
rotransmission, and homeostasis of essential metals in the
brain.50-53 In the literature,50 it hasbeenhypothesized that the
association between SLC39A8 and schizophrenia may be as-
sociatedwith its involvement inproinflammatory immune re-
sponse during brain development. Our findings highlight a
negative regulation of SLC39A8 on the nuclear factor-κ B
(NFκB) pathway54 as a putative causalmechanism. TheNFκB
pathway induces the expression of proinflammatory genes
(eg, cytokines),55 which have been associated with schizo-
phrenic symptoms.56 Inhealthypopulations, the strong asso-
ciation between SLC39A8 and putamen volumemay be asso-
ciated with the regulatory role of NFκB in the growth and
morphology of neurons during brain development.57 In pa-
tients with schizophrenia, the weakened association may be
owing to dysregulation of NFκB in terms of gene and protein
levels, and nuclear activation in brain tissues of patients.58
rs13107325 is a missense mutation substituting alanine (apo-
lar) with thyronine (polar) (Ala391Thy), resulting in ZIP8-
Thy391 transporting significantly lessmetal ion into the cell.59
Therefore, after the discovery of SNP rs13107325 associated
withschizophrenia riskby large-scaleGWAS,47,48,50,51 our find-
ings indicate thatmolecular pathologies of schizophreniamay
disrupt neuronal ion-mediated regulations in the develop-
ment of putamen volume.53
The IMAGEN sample of 1721 homogenous 14-year-old
healthy adolescents gave us an effect size (r = 0.21 between
rs13107325 and the left putamen clusters; r = 0.21 between
rs13107325 and the right putamenclusters) 3 times larger than
that of the UKB sample of 6932 adults heterogeneously aged
between 46 and 79 years (r = 0.06 for the left putamen clus-
ters; r = 0.07 for the right putamen clusters). The genetic fac-
torscouldexplainupto80%oftheheritabilityofbrainanatomy
(ie,GMV),ofwhichupto54%couldbecapturedbya largenum-
ber of SNPs.60 However, percentage of variance explained by
asinglegeneticvariantwasonly0.52%according to literature.8
In this study, the identifiedgeneticvariantexplainedmore than
4%of the variance in the observed volumes. Such a large uni-
variate genetic influence on the adolescent brain may be ow-
ing to less cumulative environmental impact (eg, exercises,61
stresses,62 and illnesses63,64) at a younger age. Perhaps the
analysis of adolescents could also help explainwhy this novel
association failed tobe identifiedbyprevious large-scalemeta-
analyses with heterogeneous age groups.65,66
Limitations
A limitation of this study is that we adopted a conservative
strategy in termsof Bonferroni correction for thediscovery of
significant vGWAS signal. We acknowledge that this conser-
vative procedure may give false-negative findings owing to
the sample size of the discovery study. However, if we used
the meta-analysis for the discovery by combining both the
IMAGEN samplewith the replication samples,wemight have
missed those associations that were significant in adoles-
cents only. Given that the IMAGEN participants were of simi-
lar age, future imaging genetic cohorts of healthy adolescents
may help us to identify more gene-brain associations with
smaller effect sizes. Second, the identified brain associations
of the other SNP rs7182018 were more stable across the life
span, but there is no evidence to our knowledge to date that it
is involved in thepathologyof schizophrenia. Third, the iden-
tified gene-level eQTL result didnot reachagenome-wide sig-
nificance level in theUKBECdatabase, and rs13107325wasnot
associated with expression of SLC39A8 in the GTEx (http://
www.gtexportal.org).Thismaybepartiallyowingtodifferences
in the sex ratio and racial/ethnic composition between these
2 databases. Furthermore, other levels (expression of exon,
junction, and transcripts) of eQTL analyses should also be
conducted in the future. Animal studies to test these possible
molecular mechanisms are also warranted.
Conclusions
In summary, using an innovativemethod,we identified a gene
thatpoints toapotential newmechanismassociatedwithboth
ion transporter and immune reaction for development of psy-
chopathology, inparticularassociatedwithschizophrenia.Given
thatthemajorfunctionoftheSLC39A8geneisaccessibletophar-
macologicmanipulation,67-69 we believe that these results are
crucial for discovering novel treatment for schizophrenia.
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